Legend Biotech (Legend Biotech) Gross-Profit-to-Asset % : 8.67% (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Legend Biotech Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Legend Biotech's annualized Gross Profit for the quarter that ended in Mar. 2024 was $157.0 Mil. Legend Biotech's average Total Assets over the quarter that ended in Mar. 2024 was $1,811.9 Mil. Therefore, Legend Biotech's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 was 8.67%.

Legend Biotech Gross-Profit-to-Asset % Historical Data

The historical data trend for Legend Biotech's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Legend Biotech Gross-Profit-to-Asset % Chart

Legend Biotech Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

15.98

14.85

7.47

4.21

8.86

Legend Biotech Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															0.23	10.36	11.15	10.20	8.67

Competitive Comparison of Legend Biotech's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Legend Biotech's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Legend Biotech's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Legend Biotech's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Legend Biotech's Gross-Profit-to-Asset % falls into.

Legend Biotech Gross-Profit-to-Asset % Calculation

Legend Biotech's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	140.929	/	( (1330.963	+	1848.609)	/ 2 )
	=	140.929	/	1589.786
	=	8.86 %

Legend Biotech's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	157.008	/	( (1848.609	+	1775.107)	/ 2 )
	=	157.008	/	1811.858
	=	8.67 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Legend Biotech Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Legend Biotech's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Legend Biotech (Legend Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Legend Biotech Corp (NAS:LEGN) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

9LB:Germany

Address

2101 Cottontail Lane, Somerset, NJ, USA, 08873

Website

https://www.legendbiotech.com

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy is for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America.